These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 39373844

  • 21. Impact of a High-Fat Meal and Sprinkled Administration on the Bioavailability and Pharmacokinetics of Viloxazine Extended-Release Capsules (QelbreeTM) in Healthy Adult Subjects.
    Wang Z, Kosheleff AR, Adeojo LW, Odebo O, Liranso T, Schwabe S, Nasser A.
    Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):69-79. PubMed ID: 34652564
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinical Trial with a 6-Month Open-Label Extension.
    Weiss MD, Cutler AJ, Kollins SH, Donnelly GAE.
    J Child Adolesc Psychopharmacol; 2021 Nov; 31(9):610-622. PubMed ID: 34637343
    [Abstract] [Full Text] [Related]

  • 23. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH, Nagy P, Childress AC, Frick G, Yan B, Pliszka S.
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
    Weisler RH, Greenbaum M, Arnold V, Yu M, Yan B, Jaffee M, Robertson B.
    CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Cândido RCF, Menezes de Padua CA, Golder S, Junqueira DR.
    Cochrane Database Syst Rev; 2021 Jan 18; 1(1):CD013011. PubMed ID: 33460048
    [Abstract] [Full Text] [Related]

  • 28. Population Pharmacokinetics of Viloxazine Extended-Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder.
    Nasser A, Gomeni R, Wang Z, Kosheleff AR, Xie L, Adeojo LW, Schwabe S.
    J Clin Pharmacol; 2021 Dec 18; 61(12):1626-1637. PubMed ID: 34269426
    [Abstract] [Full Text] [Related]

  • 29. A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings.
    Childress AC, Cutler AJ, Marraffino A, McDonnell MA, Turnbow JM, Brams M, DeSousa NJ, Incledon B, Sallee FR, Wigal SB.
    J Child Adolesc Psychopharmacol; 2020 Feb 18; 30(1):2-14. PubMed ID: 31464511
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD.
    Johnson JK, Liranso T, Saylor K, Tulloch G, Adewole T, Schwabe S, Nasser A, Findling RL, Newcorn JH.
    J Atten Disord; 2020 Jan 18; 24(2):348-358. PubMed ID: 30924702
    [Abstract] [Full Text] [Related]

  • 32. Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study.
    Iwanami A, Saito K, Fujiwara M, Okutsu D, Ichikawa H.
    BMC Psychiatry; 2020 Oct 02; 20(1):485. PubMed ID: 33008345
    [Abstract] [Full Text] [Related]

  • 33. Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study.
    Childress AC, Marraffino A, Cutler AJ, Oh C, Brams MN.
    J Child Adolesc Psychopharmacol; 2023 Mar 02; 33(2):51-58. PubMed ID: 36809150
    [Abstract] [Full Text] [Related]

  • 34. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Wilens TE, Robertson B, Sikirica V, Harper L, Young JL, Bloomfield R, Lyne A, Rynkowski G, Cutler AJ.
    J Am Acad Child Adolesc Psychiatry; 2015 Nov 02; 54(11):916-25.e2. PubMed ID: 26506582
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
    Pliszka SR, Wilens TE, Bostrom S, Arnold VK, Marraffino A, Cutler AJ, López FA, DeSousa NJ, Sallee FR, Incledon B, Newcorn JH.
    J Child Adolesc Psychopharmacol; 2017 Aug 02; 27(6):474-482. PubMed ID: 29172680
    [Abstract] [Full Text] [Related]

  • 36. Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Nasser A, Kosheleff AR, Hull JT, Liranso T, Qin P, Busse GD, O'Neal W, Fava M, Faraone SV, Rubin J.
    J Child Adolesc Psychopharmacol; 2021 Apr 02; 31(3):214-226. PubMed ID: 33600233
    [Abstract] [Full Text] [Related]

  • 37. Viloxazine: Pediatric First Approval.
    Lamb YN.
    Paediatr Drugs; 2021 Jul 02; 23(4):403-409. PubMed ID: 34036533
    [Abstract] [Full Text] [Related]

  • 38. Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe.
    Coghill DR, Banaschewski T, Nagy P, Otero IH, Soutullo C, Yan B, Caballero B, Zuddas A.
    CNS Drugs; 2017 Jul 02; 31(7):625-638. PubMed ID: 28667569
    [Abstract] [Full Text] [Related]

  • 39. Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study.
    Babcock T, Dirks B, Adeyi B, Scheckner B.
    BMC Pharmacol Toxicol; 2012 Dec 19; 13():18. PubMed ID: 23254273
    [Abstract] [Full Text] [Related]

  • 40. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.
    Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL.
    Clin Ther; 2007 Mar 19; 29(3):450-63. PubMed ID: 17577466
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.